Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clearside Biomedical ( (CLSDQ) ) just unveiled an announcement.
Clearside Biomedical, Inc., which filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware on November 23, 2025, advanced its court-supervised sale process in December 2025 by securing approval of auction and bidding procedures for a sale of all or substantially all of its assets. On December 17, 2025, the company designated Health Ocean Limited, or its assignee, as the stalking horse bidder, and on December 19, 2025, the court approved both the bidding framework and that designation, making the stalking horse offer the minimum bid for any competing proposals. The company also filed its initial monthly operating report for the period November 23–30, 2025, showing no full-time employees, negative equity of roughly $26.9 million, prepetition unsecured debt of about $2.3 million, postpetition debt of about $0.27 million, and a net loss of about $0.49 million for the short reporting period, underscoring the financial distress driving the restructuring and potential asset sale that will be closely watched by creditors and other stakeholders.
The most recent analyst rating on (CLSDQ) stock is a Sell with a $0.66 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSDQ Stock Forecast page.
Spark’s Take on CLSDQ Stock
According to Spark, TipRanks’ AI Analyst, CLSDQ is a Underperform.
Clearside Biomedical’s overall stock score is severely impacted by its poor financial performance, negative technical indicators, unattractive valuation, and significant negative corporate events, including bankruptcy and delisting from Nasdaq. These factors collectively indicate high risk and uncertainty for investors.
To see Spark’s full report on CLSDQ stock, click here.
More about Clearside Biomedical
Clearside Biomedical is a biopharmaceutical company focused on developing therapies for eye diseases, operating in the life sciences sector with a specialization in ophthalmic treatments. The company’s activities are currently centered on managing its insolvency proceedings rather than active commercial operations, as indicated by its Chapter 11 status and lack of full-time employees at the time of the latest report.
Average Trading Volume: 269,550
Technical Sentiment Signal: Sell
Current Market Cap: $3.72M
Learn more about CLSDQ stock on TipRanks’ Stock Analysis page.